Tsang-pai Liu

92 Chung Shan North Road
TPQ 10449, Taiwan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.

LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.

Journal: Biology direct
Published: December 03, 2025

Nedd4 family interacting protein 1 (NDFIP1) is a novel target of PF-429242 in promoting autophagy in hepatocellular carcinoma cells.

Nedd4 family interacting protein 1 (NDFIP1) is a novel target of PF-429242 in promoting autophagy in hepatocellular carcinoma cells.

Journal: Biochemical and biophysical research communications
Published: August 06, 2025

The combination of PF-429242 and chloroquine triggers pH-dependent cell death in hepatocellular carcinoma cells.

The combination of PF-429242 and chloroquine triggers pH-dependent cell death in hepatocellular carcinoma cells.

Journal: International journal of medical sciences
Published: December 19, 2024

Risk of Malnutrition in Adults Who Have Undergone Sleeve Gastrectomy: A Retrospective Study.

Risk of Malnutrition in Adults Who Have Undergone Sleeve Gastrectomy: A Retrospective Study.

Journal: Nutrients
Published: July 17, 2023

PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling.

PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling.

Journal: American journal of cancer research
Published: May 18, 2023

Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.

Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.

Journal: Toxicology and applied pharmacology
Published: February 23, 2023

Bridging Size and Charge Effects of Mesoporous Silica Nanoparticles for Crossing the Blood-Brain Barrier.

Bridging Size and Charge Effects of Mesoporous Silica Nanoparticles for Crossing the Blood-Brain Barrier.

Journal: Frontiers in chemistry
Published: April 29, 2022

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene.

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene.

Journal: Journal of personalized medicine
Published: October 12, 2021

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.

Journal: International journal of molecular sciences
Published: March 27, 2021

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.

Journal: Journal of clinical medicine
Published: November 03, 2020

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.

Journal: Biomolecules
Published: October 30, 2019

Osteocalcin is an Independent Predictor for Hungry Bone Syndrome After Parathyroidectomy.

Osteocalcin is an Independent Predictor for Hungry Bone Syndrome After Parathyroidectomy.

Journal: World journal of surgery
Published: October 30, 2019
Showing 1-12 of 49

Last Updated: 09/26/2026